Single-site, Open-label, Randomized, Cross-over Study in Healthy Japanese Subjects to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (2 mg/24 h) Comparing 2 Different Formulations

Trial Profile

Single-site, Open-label, Randomized, Cross-over Study in Healthy Japanese Subjects to Evaluate the Bioequivalence of Single Dose Rotigotine Transdermal Patch (2 mg/24 h) Comparing 2 Different Formulations

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Rotigotine (Primary)
  • Indications Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors UCB Pharma Inc
  • Most Recent Events

    • 01 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
    • 27 Jun 2012 Planned end date changed from 1 Jun 2012 to 1 Jul 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top